AstraZeneca AB

38 articles about AstraZeneca AB

• LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

  6/18/2019

  AstraZeneca and Merck announced that the European Commission has approved LYNPARZA as monotherapy for the maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response following completion of first-line platinum-based chemotherapy.

• CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

  6/15/2019

  An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

• AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting

  5/16/2019

  AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA® and IMFINZI® at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 to June 4, 2019.

• First and Only PARP Inhibitor, Lynparza® (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer - May 8, 2019

  5/8/2019

  AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy

• AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer

  5/8/2019

  Test It Back campaign encourages patients newly diagnosed with non-small cell lung cancer to ensure they receive a full diagnosis and the treatment that is right for them

• LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer

  4/29/2019

  AstraZeneca and Merck’s LYNPARZA Is the Only PARP Inhibitor in This Setting to Demonstrate an Improvement in Progression-Free Survival for Patients Who Responded to Platinum-Based Chemotherapy

• Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer

  4/29/2019

  20.7 months median duration of response achieved in patients with HER2 positive metastatic breast cancer previously treated with T-DM1

• Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

  4/1/2019

  Designation based on Phase II SPRINT trial in pediatric patients with NF1 plexiform neurofibromas

• Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

  4/1/2019

  Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas

• Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)

  3/28/2019

  Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates; AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia

• Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

  3/26/2019

  Ichor® Medical Systems, Inc. announced that it has entered into a collaboration and research license agreement with AstraZeneca for the development and clinical assessment of plasmid DNA constructs.

• LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

  2/26/2019

  AstraZeneca and Merck’s LYNPARZA Is the First PARP Inhibitor to Demonstrate Benefit in gBRCAm Metastatic Pancreatic Cancer in a Phase 3 Trial

• LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

  2/26/2019

  AstraZeneca and Merck’s LYNPARZA is the first PARP inhibitor to demonstrate benefit in gBRCAm metastatic pancreatic cancer in a Phase III Trial

• BRILINTA’s Phase III THEMIS Trial Met Primary Endpoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes

  2/25/2019

  BRILINTA reduced cardiovascular events in these patients with no prior heart attack or stroke

• Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy

  9/5/2018

  Biohaven Pharmaceutical Holding Company Ltd. announced today that it entered into an exclusive, worldwide license agreement, through its subsidiary Biohaven Therapeutics Ltd., with AstraZeneca AB for the development and commercialization rights to AZD3241

• Week In Review: AstraZeneca AB Commits $800 Million To China

  12/21/2015

• Cerulean Pharma Inc. Announces Clinical Collaboration With AstraZeneca AB And The National Cancer Institute To Evaluate The Combination Of LYNPARZA And CRLX101

  11/17/2015

• AstraZeneca AB Looks to Charles River Laboratories (Massachusetts) for in Vivo Biology

  10/17/2012

• AstraZeneca AB Release: Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins

  3/27/2012

• AstraZeneca AB Announces First Direct-to-Patient Program Offering the Brand ARIMIDEX® (anastrozole) Tablets to Patients for Only $40 Per Month

  2/16/2012